These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33226173)

  • 1. Use of oclacitinib as antipruritic drug during sarcoptic mange infestation treatment.
    Cornegliani L; Guidi E; Vercelli A
    Vet Dermatol; 2020 Dec; 31(6):505. PubMed ID: 33226173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
    Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica™), for the treatment of sarcoptic mange in dogs.
    Becskei C; De Bock F; Illambas J; Cherni JA; Fourie JJ; Lane M; Mahabir SP; Six RH
    Vet Parasitol; 2016 May; 222():56-61. PubMed ID: 26928658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of orally and topically administered fluralaner (Bravecto
    Chiummo R; Petersen I; Plehn C; Zschiesche E; Roepke R; Thomas E
    Parasit Vectors; 2020 Oct; 13(1):524. PubMed ID: 33069261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
    Gadeyne C; Little P; King VL; Edwards N; Davis K; Stegemann MR
    Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
    Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
    Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
    Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fluralaner in 17 dogs with sarcoptic mange.
    Romero C; Heredia R; Pineda J; Serrano JA; Mendoza GD; Trápala P; Cordero AM
    Vet Dermatol; 2016 Oct; 27(5):353-e88. PubMed ID: 27511592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
    Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
    Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of canine sarcoptic mange with afoxolaner (NexGard
    Hampel V; Knaus M; Schäfer J; Beugnet F; Rehbein S
    Parasite; 2018; 25():63. PubMed ID: 30516132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Simpson AC; Schissler JR; Rosychuk RAW; Moore AR
    Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics.
    Gonzales AJ; Fleck TJ; Humphrey WR; Galvan BA; Aleo MM; Mahabir SP; Tena JK; Greenwood KG; McCall RB
    Vet Dermatol; 2016 Feb; 27(1):34-e10. PubMed ID: 26666963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of afoxolaner plus milbemycin oxime and afoxolaner alone as treatment for sarcoptic mange in naturally infested dogs.
    Romero-Núñez C; Bautista-Gómez LG; Sheinberg G; Martín-Cordero A; Flores-Ortega A; Heredia-Cárdenas R
    Can J Vet Res; 2020 Jul; 84(3):212-216. PubMed ID: 32801456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.
    Fukuyama T; Ganchingco JR; Bäumer W
    Eur J Pharmacol; 2017 Jan; 794():20-26. PubMed ID: 27847179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis.
    Gonzales AJ; Aleo M; Mahabir S; Messamore J; Stegemann M
    J Vet Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38926932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The most effective systemic treatment in dogs with sarcoptic mange: a critically appraised topic.
    Dumitrache MO; Cadiergues MC
    BMC Vet Res; 2023 Oct; 19(1):189. PubMed ID: 37798627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
    Schäfer L; Thom N
    Vet Dermatol; 2024 Aug; 35(4):408-417. PubMed ID: 38465482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
    Carrasco I; Ferrer L; Puigdemont A
    J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crusted scabies (sarcoptic mange) in four cats due to Sarcoptes scabiei infestation.
    Malik R; McKellar Stewart K; Sousa CA; Krockenberger MB; Pope S; Ihrke P; Beatty J; Barrs VR; Walton S
    J Feline Med Surg; 2006 Oct; 8(5):327-39. PubMed ID: 16950639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.
    Gonzales AJ; Bowman JW; Fici GJ; Zhang M; Mann DW; Mitton-Fry M
    J Vet Pharmacol Ther; 2014 Aug; 37(4):317-24. PubMed ID: 24495176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.